Compare Ford Motor Company (F) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Sanofi SA — how do they compare? Ford Motor Company trades at $12.3 (market cap $48.33B), while Sanofi SA trades at $40.2 (market cap $96.81B). The key difference: Sanofi SA is far larger — about 2× Ford Motor Company's market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and Sanofi SA for 94 Days on average.
| F | SNY | |
|---|---|---|
Market Cap | $48.33B | $96.81B |
Volume | 33,572,159 | 2,081,815 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $52.34 |
52-Week Low | $11.21 | $39.51 |
Typical Hold Time | 104 Days | 94 Days |
Enterprise Value | $180.29B | $116.20B |
Dividend Yield | 4.95% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.25, down 0.2% with bearish technical signals. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Despite $187.3B revenue in 2025, net income was -$8.18B with negative margins. Analyst consensus is mixed with 38% buy ratings and a $15.90 price target. Recent news highlights sales declines and production challenges, though the company maintains strong cash flow from operations.
Ford faces significant headwinds including declining sales, negative profitability, and high debt levels. The stock offers value with low P/E (11.21) and P/S (0.26) ratios, but execution risks and competitive pressures from Asian automakers pose challenges. The dividend provides income support, but investors should weigh fundamental weaknesses against valuation appeal.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
